Overview

Seroquel ® in Patients With Bipolar Disorder in Remission With Signs of Impaired Impulse Control

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this study, the task was to evaluate the effectiveness of prescribing small doses of quetiapine (25-75 mg) for bipolar patients in remission in order to relieve symptoms of impulsivity.
Phase:
N/A
Details
Lead Sponsor:
Federal Stare Budgetary Scientific Institution, Mental Health Research Center
Collaborators:
Federal State Budgetary Institution V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, Saint-Petersburg, Russia
Kazan State Medical University
Treatments:
Quetiapine Fumarate